Why Array Technologies, Inc. (ARRY) is a Top Value Stock for the Long-Term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.
Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.
Why Investors Should Pay Attention to This Value Stock
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.
Array Technologies, Inc. (ARRY)
Boulder, CO-based Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs for treating cancer and other high-burden diseases. The company has one marketed combination therapy in its portfolio – Braftovi (encorafenib) plus Mektovi (binimetinib). The therapy is approved for treating unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. The company is also conducting label expansion studies for the combination therapy.
ARRY boasts a Value Style Score of B and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Shares of Array Technologies, Inc. are trading at a forward earnings multiple of 16X, as well as a PEG Ratio of 0.3, a Price/Cash Flow ratio of 12.2X, and a Price/Sales ratio of 1.5X.
Value investors don't just pay attention to a company's valuation ratios; positive earnings play a crucial role, too. Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2023. The Zacks Consensus Estimate has increased $0.00 to $1.03 per share. ARRY has an average earnings surprise of 245.7%.
With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding ARRY to their portfolios.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Array Technologies, Inc. (ARRY) : Free Stock Analysis Report
